Quarterly ResultMay 11, 2026, 05:27 PM
Sanara MedTech Q1 Net Revenue +19% to $27.8M; EPS $0.04
AI Summary
Sanara MedTech Inc. reported strong first-quarter 2026 financial results, with net revenue increasing 19% to $27.8 million and achieving GAAP net profitability of $0.04 per diluted share from continuing operations, compared to a net loss in the prior year. The company's strategic realignment to focus solely on the surgical market, coupled with sales team expansion, drove these results. Sanara MedTech reaffirmed its full-year 2026 net revenue guidance of $116 million to $121 million.
Key Highlights
- Net revenue increased 19% to $27.8 million in Q1 2026, up from $23.4 million in Q1 2025.
- Net income from continuing operations was $0.4 million, or $0.04 per diluted share, reversing a $0.6 million loss in Q1 2025.
- Gross profit rose 20% to $25.9 million, with gross margin improving to 93% from 92% year-over-year.
- Adjusted EBITDA increased 58% to $4.3 million, compared to $2.7 million in the prior year quarter.
- Soft tissue repair product sales grew 21% to $24.9 million.
- Cash balance was $13.6 million and long-term debt was $46.2 million as of March 31, 2026.
- Reaffirmed full-year 2026 net revenue guidance of $116 million to $121 million, representing 13% to 17% growth.
- Q2 2026 net revenue is expected to range from $28.5 million to $29.5 million, growing 10% to 14%.
Price Impact
More from SMTI